Harlan Shannon, who was also a senior scientist within the division of CNS research at Eli Lilly and Company. Research DescriptionĪs a highly trained in vivo neuropharmacologist and neuroscientist with expertise in the use of biochemical, neurochemical, behavioral and imaging methodologies, I am interested in understanding how modulation of different muscarinic acetylcholine receptor (mAChR) and/or metabotropic glutamate receptor (mGluR) subtypes in limbic and cortical brain regions influence normal affective and cognitive functions and contribute to the underlying pathophysiology of various central nervous system (CNS) disorders, such as schizophrenia, Alzheimer’s disease (AD), depression and addiction.ĭuring my graduate studies at Indiana University School of Medicine, I took advantage of a unique training opportunity to acquire expertise in small molecule drug discovery under the mentorship of my graduate mentor Dr.
Her In Vivo Pharmacology team is dedicated to utilizing translational approaches, including assessment of changes in behavior, neurochemistry and imaging endpoints such as PET and functional MRI, to explore the underlying mechanisms of novel ligands targeting different G protein-coupled receptors (GPCR) and transporters within the CNS and the implications of these effects on different disease states, most notably schizophrenia. Jones joined the Vanderbilt Center for Neuroscience Drug Discovery in 2005, and now serves as the Director of Behavioral Pharmacology and is an Assistant Professor of Pharmacology. Jones embarked on further postdoctoral studies within Vanderbilt University’s Department of Pharmacology.ĭr. While obtaining her Ph.D., she began her work in the Neuroscience division of pharmacology at Lily Research Laboratories, starting in 2001 on her first Postdoctoral Research Fellowship there.
from the Indiana University School of Medicine. in Biology from Indiana University and further completed her Ph.D.
0 kommentar(er)
